# OnCo record tucidinostat (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tucidinostat/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tucidinostat" ;
  schema:name "Tucidinostat (chidamide)"@en ;
  schema:alternateName "Chidamide"@en, "Epidaza" ;
  schema:description "Chidamide, approved in 2014, was the first epigenetic cancer drug invented in China and the first oral drug of its kind anywhere, used for T-cell lymphoma and, with hormone therapy, for breast cancer."@en ;
  schema:url <https://onco.cc/drugs/tucidinostat/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chidamide> ;
  schema:citation <https://www.chipscreen.com/en/>, <https://doi.org/10.1016/S1470-2045(19)30164-0>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule oral subtype-selective HDAC inhibitor" ;
  onco:approval "China 2014: Relapsed or refractory peripheral T-cell lymphoma", "China 2019: HR-positive, HER2-negative advanced breast cancer with exemestane after endocrine therapy (ACE)", "Japan 2021: Relapsed or refractory adult T-cell leukaemia-lymphoma (HBI-8000)" ;
  onco:cancers <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:companies <https://onco.cc/companies/chipscreen/> ;
  onco:trials <https://onco.cc/trials/nct06497985/>, <https://onco.cc/trials/nct06776952/>, <https://onco.cc/trials/nct05833724/>, <https://onco.cc/trials/nct04668690/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-jiang-lancet-oncol/> .